# xDRIVE in Metastatic Colorectal Cancer

> **NCT06929338** · — · NOT_YET_RECRUITING · sponsor: **First Ascent Biomedical Inc.** · enrollment: 30 (estimated)

## Conditions studied

- Metastatic Colon Adenocarcinoma
- Metastatic Colon Cancer
- Metastatic Rectal Adenocarcinoma
- Metastatic Rectal Carcinoma
- Metastatic Rectum Cancer

## Interventions

- **DIAGNOSTIC_TEST:** Functional precision medicine

## Key facts

- **NCT ID:** NCT06929338
- **Lead sponsor:** First Ascent Biomedical Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-15
- **Primary completion:** 2026-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-09-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06929338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06929338, "xDRIVE in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06929338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*